Eric C. McGary, MD, PhD ...

Dr. Eric C. McGary

Claim this profile

Kaiser Permanente-Anaheim

Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
11 reported clinical trials
19 drugs studied

Area of expertise

1

Lung Cancer

Eric C. McGary has run 9 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage III
Stage II
2

Non-Small Cell Lung Cancer

Eric C. McGary has run 9 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:

Stage IV
Stage III
Stage II

Affiliated Hospitals

Image of trial facility.

Kaiser Permanente-Anaheim

Image of trial facility.

Kaiser Permanente-Fontana

Clinical Trials Eric C. McGary is currently running

Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.

Recruiting

2 awards

Phase 3

27 criteria

Image of trial facility.

Tepotinib + Ramucirumab

for Lung Cancer

This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places in the body (stage IV) or that has come back after a period of improvement (recurrent). Tepotinib is used in patients whose cancer has a mutated (changed) form of a gene called MET. It is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal MET protein that signals tumor cells to multiply. This helps slow or stop the spread of tumor cells. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Giving tepotinib with ramucirumab may lower the chance of the cancer from growing or spreading in patients with stage IV or recurrent non-small cell lung cancer.

Recruiting

1 award

Phase 2

4 criteria

More about Eric C. McGary

Clinical Trial Related

11 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 3 Active Clinical Trials

Treatments Eric C. McGary has experience with

  • Pembrolizumab
  • Carboplatin
  • Pemetrexed
  • Ramucirumab
  • Crizotinib
  • Paclitaxel

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Eric C. McGary specialize in?

Is Eric C. McGary currently recruiting for clinical trials?

Are there any treatments that Eric C. McGary has studied deeply?

What is the best way to schedule an appointment with Eric C. McGary?

What is the office address of Eric C. McGary?

Is there any support for travel costs?